Fosfomycin in continuous or prolonged infusion for systemic bacterial infections: a systematic review of its dosing regimen proposal from in ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2021-02-18

AUTHORS

Roberta Maria Antonello, Stefano Di Bella, Alberto Enrico Maraolo, Roberto Luzzati

ABSTRACT

Fosfomycin (FOS) administered intravenously has been recently rediscovered for the treatment of systemic infections due to multidrug-resistant bacteria. Its pharmacokinetic properties suggest a time-dependent dosing schedule with more clinical benefits from prolonged (PI) or continuous infusion (CI) than from intermittent infusion. We revised literature concerning PI and CI FOS to identify the best dosing regimen based on current evidence. We performed a MEDLINE/PubMed search. Ninety-one studies and their pertinent references were screened. Seventeen studies were included in the present review. The activity of FOS against Gram-negative and Gram-positive bacteria was evaluated in fourteen and five studies, respectively. Six studies evaluated FOS activity in combination with another antibiotic. Daily dosing of 12, 16, 18 or 24 g, administered with different schedules, were investigated. These regimens resulted active against the tested isolates in most cases. Emergence of resistant isolates has been shown to be preventable through the coadministration of another active antibiotic. FOS is a promising option to treat systemic infections caused by multidrug-resistant bacteria. Coadministration with another active molecule is required to prevent the emergence of resistant bacterial strains. The results of our review suggest that a therapeutic regimen including a loading dose of FOS 8 g followed by a daily dose of 16 g or 24 g CI could be the best therapeutic approach for patients with normal renal function. The dosing regimens in patients with renal insufficiency and CI or PI superiority compared with intermittent infusion in clinical settings should be further investigated. More... »

PAGES

1117-1126

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10096-021-04181-x

DOI

http://dx.doi.org/10.1007/s10096-021-04181-x

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1135455542

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/33604721


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anti-Bacterial Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bacteria", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bacterial Infections", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Resistance, Multiple, Bacterial", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fosfomycin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Infusions, Intravenous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Clinical Department of Medical, Surgical and Health Sciences, Trieste University, 34127 Trieste, Italy", 
          "id": "http://www.grid.ac/institutes/grid.5133.4", 
          "name": [
            "Clinical Department of Medical, Surgical and Health Sciences, Trieste University, 34127 Trieste, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Antonello", 
        "givenName": "Roberta Maria", 
        "id": "sg:person.015001711013.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015001711013.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinical Department of Medical, Surgical and Health Sciences, Trieste University, 34127 Trieste, Italy", 
          "id": "http://www.grid.ac/institutes/grid.5133.4", 
          "name": [
            "Clinical Department of Medical, Surgical and Health Sciences, Trieste University, 34127 Trieste, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Di Bella", 
        "givenName": "Stefano", 
        "id": "sg:person.01156176207.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01156176207.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "First Division of Infectious Diseases, Cotugno Hospital, AORN dei Colli, 80131 Naples, Italy", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "First Division of Infectious Diseases, Cotugno Hospital, AORN dei Colli, 80131 Naples, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Maraolo", 
        "givenName": "Alberto Enrico", 
        "id": "sg:person.01211616664.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01211616664.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinical Department of Medical, Surgical and Health Sciences, Trieste University, 34127 Trieste, Italy", 
          "id": "http://www.grid.ac/institutes/grid.5133.4", 
          "name": [
            "Clinical Department of Medical, Surgical and Health Sciences, Trieste University, 34127 Trieste, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Luzzati", 
        "givenName": "Roberto", 
        "id": "sg:person.0740455776.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0740455776.60"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/s41598-019-53714-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1122747274", 
          "https://doi.org/10.1038/s41598-019-53714-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003495-199753040-00007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013045058", 
          "https://doi.org/10.2165/00003495-199753040-00007"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40121-020-00342-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1131099370", 
          "https://doi.org/10.1007/s40121-020-00342-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf02447919", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050649293", 
          "https://doi.org/10.1007/bf02447919"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40265-013-0168-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003597975", 
          "https://doi.org/10.1007/s40265-013-0168-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf01961855", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046086478", 
          "https://doi.org/10.1007/bf01961855"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf01640831", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000241100", 
          "https://doi.org/10.1007/bf01640831"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2021-02-18", 
    "datePublishedReg": "2021-02-18", 
    "description": "Fosfomycin (FOS) administered intravenously has been recently rediscovered for the treatment of systemic infections due to multidrug-resistant bacteria. Its pharmacokinetic properties suggest a time-dependent dosing schedule with more clinical benefits from prolonged (PI) or continuous infusion (CI) than from intermittent infusion. We revised literature concerning PI and CI FOS to identify the best dosing regimen based on current evidence. We performed a MEDLINE/PubMed search. Ninety-one studies and their pertinent references were screened. Seventeen studies were included in the present review. The activity of FOS against Gram-negative and Gram-positive bacteria was evaluated in fourteen and five studies, respectively. Six studies evaluated FOS activity in combination with another antibiotic. Daily dosing of 12, 16, 18 or 24 g, administered with different schedules, were investigated. These regimens resulted active against the tested isolates in most cases. Emergence of resistant isolates has been shown to be preventable through the coadministration of another active antibiotic. FOS is a promising option to treat systemic infections caused by multidrug-resistant bacteria. Coadministration with another active molecule is required to prevent the emergence of resistant bacterial strains. The results of our review suggest that a therapeutic regimen including a loading dose of FOS 8 g followed by a daily dose of 16 g or 24 g CI could be the best therapeutic approach for patients with normal renal function. The dosing regimens in patients with renal insufficiency and CI or PI superiority compared with intermittent infusion in clinical settings should be further investigated.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s10096-021-04181-x", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1093599", 
        "issn": [
          "0934-9723", 
          "1435-4373"
        ], 
        "name": "European Journal of Clinical Microbiology & Infectious Diseases", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "40"
      }
    ], 
    "keywords": [
      "continuous infusion", 
      "multidrug-resistant bacteria", 
      "intermittent infusion", 
      "systemic infection", 
      "MEDLINE/PubMed search", 
      "more clinical benefits", 
      "best dosing regimen", 
      "normal renal function", 
      "best therapeutic approach", 
      "systemic bacterial infection", 
      "activity of fosfomycin", 
      "renal function", 
      "renal insufficiency", 
      "dosing schedules", 
      "daily dosing", 
      "loading dose", 
      "dosing regimen", 
      "therapeutic regimen", 
      "daily dose", 
      "clinical benefit", 
      "prolonged infusion", 
      "clinical studies", 
      "therapeutic approaches", 
      "current evidence", 
      "PubMed search", 
      "systematic review", 
      "bacterial infections", 
      "Fos activity", 
      "infusion", 
      "clinical setting", 
      "pharmacokinetic properties", 
      "resistant isolates", 
      "active antibiotics", 
      "resistant bacterial strains", 
      "fosfomycin", 
      "infection", 
      "different schedules", 
      "regimen", 
      "coadministration", 
      "patients", 
      "dose", 
      "present review", 
      "antibiotics", 
      "pertinent references", 
      "review", 
      "Gram-positive bacteria", 
      "most cases", 
      "regimens", 
      "isolates", 
      "dosing", 
      "insufficiency", 
      "study", 
      "promising option", 
      "treatment", 
      "schedule", 
      "activity", 
      "vivo", 
      "bacteria", 
      "bacterial strains", 
      "options", 
      "setting", 
      "active molecules", 
      "evidence", 
      "cases", 
      "benefits", 
      "strains", 
      "Gram", 
      "search", 
      "combination", 
      "function", 
      "emergence", 
      "literature", 
      "PI", 
      "results", 
      "molecules", 
      "superiority", 
      "reference", 
      "approach", 
      "properties", 
      "proposal", 
      "time-dependent dosing schedule", 
      "CI FOS", 
      "PI superiority", 
      "regimen proposal"
    ], 
    "name": "Fosfomycin in continuous or prolonged infusion for systemic bacterial infections: a systematic review of its dosing regimen proposal from in vitro, in vivo and clinical studies", 
    "pagination": "1117-1126", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1135455542"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10096-021-04181-x"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "33604721"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10096-021-04181-x", 
      "https://app.dimensions.ai/details/publication/pub.1135455542"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:59", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_882.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s10096-021-04181-x"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10096-021-04181-x'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10096-021-04181-x'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10096-021-04181-x'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10096-021-04181-x'


 

This table displays all metadata directly associated to this object as RDF triples.

238 TRIPLES      22 PREDICATES      127 URIs      112 LITERALS      17 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10096-021-04181-x schema:about N44ac731653a949db88cfab97a8da6486
2 N51d8ddba359444a9be15162fed04e88f
3 N5e4c7b3042de411383fda4bed527d7cc
4 N66f140b428f643ce8b98736e8af29589
5 N9c7c495cb0824b0cb582830b12a9ded0
6 Nb72ea1b2533b4d89b9ce7c81c966ce89
7 Ne42e363db21043248929ccdfb0a0e3d3
8 Ne5dec2eaff6448f3899343085cfaef15
9 Nf0fbafd710404ee6b7e4b39a52c8bd51
10 Nfdb361c66b7345ac864699e31e05cc31
11 anzsrc-for:11
12 anzsrc-for:1103
13 schema:author Nb90940d1ba344a249138b0ee78f09351
14 schema:citation sg:pub.10.1007/bf01640831
15 sg:pub.10.1007/bf01961855
16 sg:pub.10.1007/bf02447919
17 sg:pub.10.1007/s40121-020-00342-1
18 sg:pub.10.1007/s40265-013-0168-2
19 sg:pub.10.1038/s41598-019-53714-0
20 sg:pub.10.2165/00003495-199753040-00007
21 schema:datePublished 2021-02-18
22 schema:datePublishedReg 2021-02-18
23 schema:description Fosfomycin (FOS) administered intravenously has been recently rediscovered for the treatment of systemic infections due to multidrug-resistant bacteria. Its pharmacokinetic properties suggest a time-dependent dosing schedule with more clinical benefits from prolonged (PI) or continuous infusion (CI) than from intermittent infusion. We revised literature concerning PI and CI FOS to identify the best dosing regimen based on current evidence. We performed a MEDLINE/PubMed search. Ninety-one studies and their pertinent references were screened. Seventeen studies were included in the present review. The activity of FOS against Gram-negative and Gram-positive bacteria was evaluated in fourteen and five studies, respectively. Six studies evaluated FOS activity in combination with another antibiotic. Daily dosing of 12, 16, 18 or 24 g, administered with different schedules, were investigated. These regimens resulted active against the tested isolates in most cases. Emergence of resistant isolates has been shown to be preventable through the coadministration of another active antibiotic. FOS is a promising option to treat systemic infections caused by multidrug-resistant bacteria. Coadministration with another active molecule is required to prevent the emergence of resistant bacterial strains. The results of our review suggest that a therapeutic regimen including a loading dose of FOS 8 g followed by a daily dose of 16 g or 24 g CI could be the best therapeutic approach for patients with normal renal function. The dosing regimens in patients with renal insufficiency and CI or PI superiority compared with intermittent infusion in clinical settings should be further investigated.
24 schema:genre article
25 schema:inLanguage en
26 schema:isAccessibleForFree true
27 schema:isPartOf Nc0d1b62e1da9402e8d3d944e474dcafa
28 Nf69a709580a14996a65e5e254ececb09
29 sg:journal.1093599
30 schema:keywords CI FOS
31 Fos activity
32 Gram
33 Gram-positive bacteria
34 MEDLINE/PubMed search
35 PI
36 PI superiority
37 PubMed search
38 active antibiotics
39 active molecules
40 activity
41 activity of fosfomycin
42 antibiotics
43 approach
44 bacteria
45 bacterial infections
46 bacterial strains
47 benefits
48 best dosing regimen
49 best therapeutic approach
50 cases
51 clinical benefit
52 clinical setting
53 clinical studies
54 coadministration
55 combination
56 continuous infusion
57 current evidence
58 daily dose
59 daily dosing
60 different schedules
61 dose
62 dosing
63 dosing regimen
64 dosing schedules
65 emergence
66 evidence
67 fosfomycin
68 function
69 infection
70 infusion
71 insufficiency
72 intermittent infusion
73 isolates
74 literature
75 loading dose
76 molecules
77 more clinical benefits
78 most cases
79 multidrug-resistant bacteria
80 normal renal function
81 options
82 patients
83 pertinent references
84 pharmacokinetic properties
85 present review
86 prolonged infusion
87 promising option
88 properties
89 proposal
90 reference
91 regimen
92 regimen proposal
93 regimens
94 renal function
95 renal insufficiency
96 resistant bacterial strains
97 resistant isolates
98 results
99 review
100 schedule
101 search
102 setting
103 strains
104 study
105 superiority
106 systematic review
107 systemic bacterial infection
108 systemic infection
109 therapeutic approaches
110 therapeutic regimen
111 time-dependent dosing schedule
112 treatment
113 vivo
114 schema:name Fosfomycin in continuous or prolonged infusion for systemic bacterial infections: a systematic review of its dosing regimen proposal from in vitro, in vivo and clinical studies
115 schema:pagination 1117-1126
116 schema:productId N19b217203ee24972944de0a1c2a2926a
117 N1e6795d11e4342e59fe12d93b2250a5d
118 Nbc1697b073e04afb9e8886f42ead655c
119 schema:sameAs https://app.dimensions.ai/details/publication/pub.1135455542
120 https://doi.org/10.1007/s10096-021-04181-x
121 schema:sdDatePublished 2022-01-01T18:59
122 schema:sdLicense https://scigraph.springernature.com/explorer/license/
123 schema:sdPublisher N2dde4efd1b784a0aafbeabdd468a82ae
124 schema:url https://doi.org/10.1007/s10096-021-04181-x
125 sgo:license sg:explorer/license/
126 sgo:sdDataset articles
127 rdf:type schema:ScholarlyArticle
128 N19b217203ee24972944de0a1c2a2926a schema:name dimensions_id
129 schema:value pub.1135455542
130 rdf:type schema:PropertyValue
131 N1e6795d11e4342e59fe12d93b2250a5d schema:name doi
132 schema:value 10.1007/s10096-021-04181-x
133 rdf:type schema:PropertyValue
134 N2dde4efd1b784a0aafbeabdd468a82ae schema:name Springer Nature - SN SciGraph project
135 rdf:type schema:Organization
136 N44ac731653a949db88cfab97a8da6486 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Drug Administration Schedule
138 rdf:type schema:DefinedTerm
139 N4552997417994b24a4d012ec8d0f954f rdf:first sg:person.01156176207.36
140 rdf:rest N4a777f0ead284340808f10de7c8f16fe
141 N4a777f0ead284340808f10de7c8f16fe rdf:first sg:person.01211616664.17
142 rdf:rest N762a714c6bae46009d2ac7ee7ee16a4c
143 N51d8ddba359444a9be15162fed04e88f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Humans
145 rdf:type schema:DefinedTerm
146 N5e4c7b3042de411383fda4bed527d7cc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Infusions, Intravenous
148 rdf:type schema:DefinedTerm
149 N66f140b428f643ce8b98736e8af29589 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Dose-Response Relationship, Drug
151 rdf:type schema:DefinedTerm
152 N762a714c6bae46009d2ac7ee7ee16a4c rdf:first sg:person.0740455776.60
153 rdf:rest rdf:nil
154 N9c7c495cb0824b0cb582830b12a9ded0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Time Factors
156 rdf:type schema:DefinedTerm
157 Nb72ea1b2533b4d89b9ce7c81c966ce89 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Anti-Bacterial Agents
159 rdf:type schema:DefinedTerm
160 Nb90940d1ba344a249138b0ee78f09351 rdf:first sg:person.015001711013.54
161 rdf:rest N4552997417994b24a4d012ec8d0f954f
162 Nbc1697b073e04afb9e8886f42ead655c schema:name pubmed_id
163 schema:value 33604721
164 rdf:type schema:PropertyValue
165 Nc0d1b62e1da9402e8d3d944e474dcafa schema:issueNumber 6
166 rdf:type schema:PublicationIssue
167 Ne42e363db21043248929ccdfb0a0e3d3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Bacteria
169 rdf:type schema:DefinedTerm
170 Ne5dec2eaff6448f3899343085cfaef15 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Bacterial Infections
172 rdf:type schema:DefinedTerm
173 Nf0fbafd710404ee6b7e4b39a52c8bd51 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Fosfomycin
175 rdf:type schema:DefinedTerm
176 Nf69a709580a14996a65e5e254ececb09 schema:volumeNumber 40
177 rdf:type schema:PublicationVolume
178 Nfdb361c66b7345ac864699e31e05cc31 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Drug Resistance, Multiple, Bacterial
180 rdf:type schema:DefinedTerm
181 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
182 schema:name Medical and Health Sciences
183 rdf:type schema:DefinedTerm
184 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
185 schema:name Clinical Sciences
186 rdf:type schema:DefinedTerm
187 sg:journal.1093599 schema:issn 0934-9723
188 1435-4373
189 schema:name European Journal of Clinical Microbiology & Infectious Diseases
190 schema:publisher Springer Nature
191 rdf:type schema:Periodical
192 sg:person.01156176207.36 schema:affiliation grid-institutes:grid.5133.4
193 schema:familyName Di Bella
194 schema:givenName Stefano
195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01156176207.36
196 rdf:type schema:Person
197 sg:person.01211616664.17 schema:affiliation grid-institutes:None
198 schema:familyName Maraolo
199 schema:givenName Alberto Enrico
200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01211616664.17
201 rdf:type schema:Person
202 sg:person.015001711013.54 schema:affiliation grid-institutes:grid.5133.4
203 schema:familyName Antonello
204 schema:givenName Roberta Maria
205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015001711013.54
206 rdf:type schema:Person
207 sg:person.0740455776.60 schema:affiliation grid-institutes:grid.5133.4
208 schema:familyName Luzzati
209 schema:givenName Roberto
210 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0740455776.60
211 rdf:type schema:Person
212 sg:pub.10.1007/bf01640831 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000241100
213 https://doi.org/10.1007/bf01640831
214 rdf:type schema:CreativeWork
215 sg:pub.10.1007/bf01961855 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046086478
216 https://doi.org/10.1007/bf01961855
217 rdf:type schema:CreativeWork
218 sg:pub.10.1007/bf02447919 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050649293
219 https://doi.org/10.1007/bf02447919
220 rdf:type schema:CreativeWork
221 sg:pub.10.1007/s40121-020-00342-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1131099370
222 https://doi.org/10.1007/s40121-020-00342-1
223 rdf:type schema:CreativeWork
224 sg:pub.10.1007/s40265-013-0168-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003597975
225 https://doi.org/10.1007/s40265-013-0168-2
226 rdf:type schema:CreativeWork
227 sg:pub.10.1038/s41598-019-53714-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1122747274
228 https://doi.org/10.1038/s41598-019-53714-0
229 rdf:type schema:CreativeWork
230 sg:pub.10.2165/00003495-199753040-00007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013045058
231 https://doi.org/10.2165/00003495-199753040-00007
232 rdf:type schema:CreativeWork
233 grid-institutes:None schema:alternateName First Division of Infectious Diseases, Cotugno Hospital, AORN dei Colli, 80131 Naples, Italy
234 schema:name First Division of Infectious Diseases, Cotugno Hospital, AORN dei Colli, 80131 Naples, Italy
235 rdf:type schema:Organization
236 grid-institutes:grid.5133.4 schema:alternateName Clinical Department of Medical, Surgical and Health Sciences, Trieste University, 34127 Trieste, Italy
237 schema:name Clinical Department of Medical, Surgical and Health Sciences, Trieste University, 34127 Trieste, Italy
238 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...